

Compassionate Use Program (CUP)

Approved by The Norwegian Medicinal Products Agency

Active substance	Indication	Date of approval	Responsible for the CUP
CUP available for patients			
Sipavibart (AZD3151) 150 mg/mL solution for injection	Pre-exposure prophylaxis of COVID-19 for immunocompromised individuals	2024-04-10	AstraZeneca Nordic Contact person: Kristin Janett Løseth Phone: +47 21 00 64 00 Mobile phone: +47 90 08 11 65 E-mail: kristin.loseth@astrazeneca.com
Nimorazole tablets, 500 mg	Squamous cell Cancer of the Head and Neck (SCCHN)	2016-12-01	Inphena ApS Name: Søren Anker Nielsen Email: san@inphena.com Phone: (+45) 40 200 200
CUP no longer available for new patients			
Elranatamab (PF-06863135) 40mg/ml	Multiple Myeloma (MM)	2023-02-02 Ended: January 2024	Pfizer AS
Glofitamab (AG42296) 5 mg/ml solution for iv infusion	Relapsed / refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL), transformed Follicular Lymphoma (tFL) or Primary Mediastinal B-Cell Lymphoma (PMBCL)	2021-05-20	Roche Norge AS
Tebentafusp (IMCgp100) 0.2mg/mL solution for infusion	HLA-A*02:01 positive patients with unresectable or metastatic uveal melanoma	2022-01-16 Ended: May 2023	Immunocore, Ltd.
Mosunetuzumab (AG42295) 1 mg/1 mL, 10 mg/10 mL og 30 mg/30 mL	Relapsed / Refractory Follicular Lymphoma (R/R FL)	2021-10-14 Ended: 2022-10-21	Roche Norge AS

Pevonedistat (TAK-924/MLN4924) 10 mg/ml concentrate for solution for iv infusion	Higher risk myelodysplastic syndromes (HR-MDS), or low blast acute myelogenous leukemia (LB-AML)	2020-08-25	Takeda
Risdiplam (RO7034067) 60mg, mixture	Spinal muscular atrophy (SMA)	2020-05-08	Roche Norge AS
Zanamivir 10mg/ml Infusion bag.	Hospitalised patients severely ill with influenza infection	2011-02-25	GlaxoSmithKline Research & Development Limited, United Kingdom
Polatuzumabvedotin, 140mg concentrate for infusjon	Relapsed or refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)	2019-02-01	Roche Norge AS
Entrectinib capsules, 100mg, 200mg	Solid Tumors harboring a NTRK Gene Fusion or Patients with Non-Small Cell Lung Cancer (NSCLC) harboring a ROS1 Gene Fusion (AG40852)	2019-03-07	Roche Norge AS
Quizartinib tablets, 20mg and 30mg	Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations	2019-03-12	Daiichi Sankyo Inc.
Lorlatinib tablets, 5mg, 25mg, and 100mg acetate solvate tablets or as 25mg or 50mg free base tablets	Advanced non-small cell lung cancer (NSCLC) with an ALK or ROS1 gene rearrangement	2018-09-05	Pfizer Norge AS
Brigatinib tablets, 90 mg and 180 mg	ALK positive Non-Small Cell Lung Cancer	2018-04-20	Takeda Pharmaceuticals AS,
Emicizumab, 150 mg/1 ml	Hemophilia A and FVIII Inhibitors	2017-11-01	Roche Norge AS

Ocrelizumab, 300 mg intravenous infusion	Primary Progressive Multiple Sclerosis (PPMS)	2017-06-07	Roche Norge AS
Pembrolizumab, intravenous infusjon 2 mg/kg	Metastatic Melanoma	2014-09-09	MSD Norge AS
Ibrutinib capsules, 140mg	Relapsed or Refractory Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma with Deletion 17p	2014-05-06	Janssen-Cilag AB
Cobimetinib (GDC-0973) 20 mg	advanced/metastatic BRAF ^{V600} mutation-positive melanoma	2015-06-25	Roche Norge AS
Combination regimen of trametinib and dabrafenib. Dabrafenib 150 mg Trametinib 2 mg	BRAF activating mutation-positive metastatic melanoma	2015-08-22	GlaxoSmithKline (GSK) AS, Oslo
Daclatasvir, 60 mg	Chronic hepatitis C	2014-06-23	Bristol-Mayers Squibb AS
Boceprevir	Hepatitis C	2011-05-05	MSD
Abiratrone	Metastatic Advanced Prostate Cancer	2011-11-19	Jansen Cilag
Crizotinib (PF-02341066)	Cancer (Positive ALK-fusion)	2011-10-13	Pfizer
Aflibercept	Metastatic Colorectal Cancer (mCRC)	2011-09-28	Sanofi